Search Results
Your search for ,twO matches 11982 pages
Showing 4051 - 4100Expert Point of View: Christopher Flowers, MD
Commenting on this presentation, session moderator Christopher Flowers, MD, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center, Houston, said: “The treatment of adolescent and young adult patients with lymphoma remains a considerable challenge. The...
Disparities and Incidence of Late Effects of Treatment for AYA Lymphoma Survivors
The late effects of adolescent and young adults (AYA) with lymphomas are considerable and have not been given much attention, according to Theresa Keegan, MD, of the University of California at Davis. “Lymphoma is one of the most commonly occurring malignancies in AYAs,” she stated. “The 5-year...
The New Face of Medical Visits
“Good morning! I’m Dr. Saksena. It’s a pleasure to meet you.” I wave my introduction as I enter the room. Two women sit beside each other. One of them wears a mask that reads “lipstick optional,” and the other dons a surgical mask. This is a new visit for breast cancer, but I haven’t yet deciphered ...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and Didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this...
Meta-analyses of Quality of Life in Patients Treated With Checkpoint Inhibitors
Findings from two meta-analyses designed to summarize quality-of-life data on patients receiving immune checkpoint inhibitor therapy for cancer were presented at the ESMO Virtual Congress 2020 (Abstract 1568O). These meta-analyses found that patients receiving immune checkpoint inhibitors had...
Efforts to Broaden Eligibility Criteria for Clinical Trials Seek to Include More Racial and Ethnic Minority Patients
A review of the 2019 Drug Trials Snapshots Report1 from the U.S. Food and Drug Administration (FDA) showed that although female participation in clinical trials grew to 72% from 56% in the FDA’s 2018 Drug Trials Snapshots Report,2 ethnic minority participation in clinical trials actually declined...
Nivolumab Shows Activity in edPOLE-Mutated, MMR-Proficient Advanced Cancers
Nivolumab monotherapy showed high response and disease control rates in patients with pathogenic exonuclease domain POLE (edPOLE)-mutated, mismatch repair (MMR)-proficient advanced tumors containing confirmed pathogenic mutations, according to findings presented by Benoit J.C. Rousseau, MD, PhD, of ...
Use of ctDNA to Direct Therapy in Advanced Breast Cancer
In the phase IIa plasmaMATCH platform trial reported in The Lancet Oncology, Nicholas C. Turner, MD, and colleagues found that circulating tumor DNA (ctDNA) provided accurate genotyping that permitted selection of directed therapies in patients with advanced breast cancer. Study Details The...
Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
The challenge in treating patients with borderline resectable pancreatic cancer is how to render tumors resectable and how to achieve the negative surgical margins that enhance long-term survival odds. Fortunately, neoadjuvant chemotherapy is helping to achieve these important goals, according to...
Does Radical Hysterectomy Improve Survival in Patients With Cervical Cancer and Intraoperative Detection of Positive Lymph Nodes?
No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom a radical uterine procedure (mostly radical hysterectomy) was completed or abandoned upon intraoperative detection of positive pelvic lymph nodes. These...
Can Drinking Coffee Daily Improve Survival in Patients With Advanced Colorectal Cancer?
In a large group of patients with metastatic colorectal cancer, consumption of a few cups of coffee a day was associated with longer survival and reduced risk of disease progression, according to findings reported by Mackintosh et al in JAMA Oncology. The findings, based on data from a large...
Olanzapine for Children and Adolescents Receiving Highly Emetogenic Chemotherapy
In a single-center Indian phase III trial reported in the Journal of Clinical Oncology, Naik et al found that the addition of olanzapine to standard antiemetic treatment significantly increased the rate of complete response (CR; defined as no vomiting or use of rescue medication) among children and ...
Impact of Neoadjuvant Endocrine Therapy and Neoadjuvant Chemotherapy on Rates of Breast‑Conserving Surgery
“Studies that have compared neoadjuvant endocrine therapy with neoadjuvant chemotherapy have shown low pathologic complete response rates with both approaches. However, the rates of breast-conserving surgery have been shown to be slightly higher with neoadjuvant endocrine therapy,” Kelly Hunt, MD,...
Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy
Sumanta K. Pal, MD, of the City of Hope National Medical Center, discusses results from the COSMIC-021 study, which tested two different doses of cabozantinib, each with a standard dose of atezolizumab, administered to patients with metastatic advanced clear cell renal cell carcinoma. Dr. Pal...
First-Line Checkpoint Inhibitors May Improve Survival in Gastroesophageal Cancers
Immune therapy for advanced gastroesophageal cancer has taken a leap forward by showing its value in the first-line setting, according to two studies in which nivolumab and pembrolizumab, both given with chemotherapy, significantly improved overall survival vs chemotherapy alone. The studies,...
Overall Survival Analysis From PROfound Trial: Olaparib for Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine and during the ESMO Virtual Congress 2020 (Abstract 610O) by Maha Hussain, MD, FACP, FASCO, and colleagues, an overall survival analysis from the phase III PROfound trial has shown a significant benefit with olaparib vs physician’s choice of...
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there was any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) following complete resection and (neo)adjuvant chemotherapy. No difference in disease-free survival...
ESMO Virtual Congress 2020: Findings in Breast and Head and Neck Cancers
We're sharing interviews with two authors of high-impact papers on breast cancer and head and neck cancer presented at the ESMO Virtual Congress 2020.
CheckMate 9ER Trial Shows Benefit of Novel Doublet for Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib was superior to the former standard, sunitinib, as first-line treatment for advanced/metastatic renal cell carcinoma, according to results of the phase III CheckMate 9ER trial reported by Toni K. Choueiri, MD, and colleagues at the ESMO Virtual...
Maintenance Avelumab Plus Best Supportive Care in Advanced Bladder Cancer
Findings from the JAVELIN Bladder 100 trial were published by Thomas Powles, MD, and colleagues in The New England Journal of Medicine. Researchers reported that the PD-L1 inhibitor avelumab led to a 31% reduction in risk of death, and extended median survival by more than 7 months in patients with ...
Effects of the COVID-19 Pandemic on Cancer Care, Provider Well-Being
Delays and cancellation of cancer treatments and other safety measures undertaken to minimize the risk of exposure to the coronavirus have generated a backlog in oncology care and research. The threat of delayed diagnoses looms while oncology professionals face burnout, according to new studies...
ESMO 2020: Access to Treatments and Trials Varies Widely for Patients With Cancer Across Europe
Access to cancer treatments is highly unequal across Europe, both for new drugs in development (due to disparities in access to clinical trials) and for currently approved drugs (due to disparities in health-care spending by different countries), according to results from two studies being...
FDA Pipeline: Designations in Prostate Cancer, Glioblastoma, and Pediatric Leukemia
Recently, the U.S. Food and Drug Administration (FDA) granted designations to agents for metastatic castration-resistant prostate cancer, recurrent glioblastoma, and pediatric acute myeloid leukemia. Fast Track Designation for EPI-7386 in Metastatic Castration-Resistant Prostate Cancer The FDA...
Role of F-18–NaF PET/CT in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
In a phase II study reported in the Journal of Clinical Oncology, Kyriakopoulos et al found that use of quantitative total bone imaging with fluorine-18 (F-18)–sodium fluoride (NaF) positron-emission tomography/computed tomography (PET/CT) helped identify heterogeneity of response in bone lesions...
Addition of Pembrolizumab to Eribulin in HR-Positive, HER2-Negative Metastatic Breast Cancer
In a phase II trial reported in JAMA Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the addition of pembrolizumab to eribulin did not improve progression-free survival in women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer. As stated by the...
Caring for Undocumented Patients With Cancer
There are approximately 25 million foreign-born immigrants living in the United States, which is more than 13% of the nation’s total population. Of these individuals, it is estimated that about 11 million are undocumented; by far, the largest group of this immigrant undocumented population is...
Viral Load May Help Predict Mortality Rate in Hospitalized Patients With Cancer and COVID-19
Higher viral loads may be associated with a greater risk of death among patients with cancer—and individuals without cancer—hospitalized with COVID-19, according to a report by Westblade et al in Cancer Cell. Among hospitalized patients infected with COVID-19, those with hematologic malignancies...
Adjuvant Chemotherapy After Pancreatic Cancer Resection and Neoadjuvant FOLFIRINOX: Improvement in Overall Survival?
In a retrospective cohort study reported in JAMA Oncology, van Roessel et al found that adjuvant chemotherapy after pancreatic cancer resection and neoadjuvant FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was associated with an improvement in overall survival. The benefit was...
Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas
In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...
Overall Survival With Darolutamide in Patients With Nonmetastatic, Castration-Resistant Prostate Cancer: ARAMIS Trial
As reported in The New England Journal of Medicine by Karim Fizazi, MD, and colleagues, the phase III ARAMIS trial has shown significantly prolonged overall survival with darolutamide vs placebo in men with nonmetastatic castration-resistant prostate cancer. The previously reported primary analysis ...
Meta-analysis of Duration of Adjuvant Trastuzumab in Early Breast Cancer
In individual participant data and trial-level meta-analyses reported in JAMA Network Open, Gulia et al found that disease-free survival with adjuvant trastuzumab given for less than 1 year was noninferior to 1 year of trastuzumab therapy in patients with early breast cancer. In addition, the...
Enthusiastic Response to Novel Therapies on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase (CEL) modulators, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, Director of the Jerome Lipper Multiple...
Dr. Kantarjian Shares His Thoughts on Optimizing the Treatment of Adults With ALL
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor and...
Combination Immunotherapy Benefits Subset of Patients With Advanced Prostate Cancer
Results from a phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti–CTLA-4) plus nivolumab (anti–PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer, an...
Association of Immunoscore With Time to Recurrence in Stage III Colon Cancer
In a study reported in the Journal of Clinical Oncology, Mlecnik et al found that high Immunoscore values were associated with reduced risk of disease recurrence and better outcomes with chemotherapy vs no chemotherapy in patients with stage III colon cancer. Study Details The international...
Addition of Debio 1143 to Cisplatin Chemoradiotherapy in Locoregionally Advanced Head and Neck Cancer
In a French Head and Neck Radiotherapy Oncology Group phase II trial reported in The Lancet Oncology, Sun et al found that the addition of Debio 1143 (a small-molecule antagonist of inhibitor of apoptosis proteins) to high-dose cisplatin chemoradiation improved locoregional disease control in...
Phase II Trial of Capmatinib for MET Exon 14–Mutated or MET-Amplified Advanced NSCLC
As reported in The New England Journal of Medicine by Wolf et al, the phase II GEOMETRY mono-1 trial has shown durable responses with the selective MET inhibitor capmatinib in patients with advanced non–small cell lung cancer (NSCLC) and MET exon 14–skipping mutations. The trial supported the May...
Long-Term Follow-up of the COMBI-AD Trial: Adjuvant Dabrafenib/Trametinib in Patients With Stage III Melanoma and BRAF V600 Mutations
As reported in The New England Journal of Medicine by Reinhard Dummer, MD, and colleagues, 5-year follow-up of the phase III COMBI-AD trial has shown continued relapse-free survival benefit with adjuvant dabrafenib/trametinib vs placebo in patients with stage III melanoma and BRAF V600E or V600K...
First-Line Durvalumab Plus Cisplatin/Pemetrexed in Malignant Pleural Mesothelioma
As reported in The Lancet Oncology by Nowak et al, the Australian phase II DREAM trial showed activity with the triplet of durvalumab plus cisplatin/pemetrexed in previously untreated patients with advanced malignant mesothelioma. Study Details In the multicenter trial, 54 evaluable patients with...
Second-Line Carboplatin/Etoposide vs Topotecan in Relapsed Small Cell Lung Cancer
As reported in The Lancet Oncology by Baize et al, a French phase III trial has shown significant improvement in progression-free survival with second-line carboplatin plus etoposide vs topotecan in patients with chemotherapy-sensitive relapsed small cell lung cancer. As noted by the investigators, ...
Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphomas
In the TRANSCEND NHL 001 study reported in The Lancet, Jeremy S. Abramson, MD, and colleagues found that the autologous CD19-directed chimeric antigen receptor (CAR) T-cell agent lisocabtagene maraleucel (liso-cel) produced a high response rate in patients with relapsed or refractory large B-cell...
Roger H. Herzig, MD, Pioneer in the Treatment of Leukemia, Dies at Age 74
More than 5 decades ago, the concept of bone marrow transplantation to treat humans with leukemia was met with varying degrees of skepticism and countless clinical failures. Yet, over those same decades, bone marrow transplantation was transformed from an insurmountable therapeutic option used in a ...
Addition of ATR Inhibitor Berzosertib to Gemcitabine Improves Progression-Free Survival in Recurrent Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, Dana-Farber Cancer Institute, and colleagues, a U.S. Experimental Therapeutics Clinical Trials Network phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia...
Cervical Cancer Screening and Prevention in Low- and Middle-Income Countries: 2020
Cervical cancer is a worldwide public health problem. The incidence of the disease is particularly high in low- and middle-income countries, where low coverage of prevention strategies and high risk of infection persist. To reduce morbidity and mortality, improved screening and prevention are...
Simple Rapid Vinegar Screening Test Cuts Cervical Cancer Death Rates by One-Third in Rural India
In 2013, at the ASCO Annual Meeting Plenary Session, it was both surprising and encouraging in the era of personalized medicine for cancer care to hear about a simple low-tech intervention delivered by women in the community that cut the rate of death from cervical cancer in India by about...
Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the antibody-drug conjugate belantamab mafodotin-blmf was granted accelerated approval for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, ...
Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
On July 7, 2020, an oral combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine was approved for treatment of adult patients with myelodysplastic syndromes (MDS), including: Previously treated and untreated, de novo, and secondary MDS with the ...
Research Pioneer Marc L. Citron, MD, Establishes Grants Through Conquer Cancer
“Ask any doctor why he or she enters medicine and the answer will likely be the same,” said Marc L. Citron, MD. “People become doctors to help patients...but to deliver the moments that matter to patients—to extend their lives and give quality to their days—doctors rely on new research.” In 2003,...
Global Oncology Young Investigator Award: Early Support Improves Cancer Care Around the World
Global oncology refers to the application of the concepts of global health to cancer and implies an approach to the practice of oncology that acknowledges the reality of limited resources in parts of the world. The Global Oncology Young Investigator Award (YIA) from ASCO and Conquer Cancer, the...
Setting an Ambitious Path to Ensure Health Equity for All Patients With Cancer
In keeping with her Presidential theme of “Equity: Every Patient, Every Day, Everywhere,” in July, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, announced the Society was joining forces with the Association of Community Cancer Centers (ACCC) to increase racial and ethnic minority participation...
